Combining human genetics, mouse models, and molecular biology, we identified that 13 of 334 (4%) of CHH probands harbor a heterozygous loss‐of‐function mutation in KLB. No mutations were identified in FGF21. The majority of CHH probands with KLB mutations exhibit metabolic defects. The gene discussed is FGF21; the disease is cartilage-hair hypoplasia.